Development and Validation of a Method for the Quantitative Determination of Etoricoxib in Liquid Dosage Form

Introduction. Etoricoxib is a selective cyclooxygenase (COX-2) inhibitor used for the treatment of acute pain and has anti-inflammatory and analgesic efficacy. Etoricoxib causes fewer complications compared to other non-steroidal anti-inflammatory drugs (NSAIDs). FSI "SID and GP" has developed an op...

Description complète

Détails bibliographiques

Auteurs principaux:	A. Kh. Amandusova, A. E. Kovalenko, A. V. Morozov, K. R. Savelyeva, T. L. Batalova, O. A. Ostapyuk, L. V. Persanova, T. Yu. Andreevicheva, A. G. Beniashvili, V. N. Shestakov, S. V. Polyakov
Format:	Artigo
Langue:	Russo
Publié:	LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-05-01
Collection:	Разработка и регистрация лекарственных средств
Sujets:	etoricoxib liquid dosage form high performance liquid chromatography (hplc) validation
Accès en ligne:	https://www.pharmjournal.ru/jour/article/view/1488
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!